New combo therapy aims to boost survival in tough esophageal cancer cases
NCT ID NCT05189730
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests whether adding the immunotherapy drug tislelizumab to chemotherapy after standard chemoradiation can improve outcomes for people with locally advanced esophageal cancer who are at high risk. About 80 participants will receive the combination before surgery, then get more treatment based on their results. The goal is to see if this approach can help high-risk patients live longer while avoiding extra side effects for those at lower risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (an immunotherapy drug) combined with paclitaxel and carboplatin (chemotherapy drugs)
- What this could lead to
- If successful, this could lead to a more personalized treatment approach for esophageal cancer, helping high-risk patients live longer while sparing low-risk patients from unnecessary side effects.
- What could go wrong
- This is an early-phase exploratory study with only 80 participants, so results may not apply broadly. The combination therapy also carries risks of side effects from both immunotherapy and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads